ARTICLE | Company News
ICN, Metabasis deal
October 8, 2001 7:00 AM UTC
ICN will develop and market MB6866, an oral compound to treat hepatitis B virus (HBV) infection, from Metabasis. ICN will fund development and pay Metabasis a license fee, milestones and royalties. Th...